Cystic Fibrosis Pulmonary Exacerbation Clinical Trial
— PIPEOfficial title:
Randomized Controlled Trial of Prednisone in Cystic Fibrosis Pulmonary Exacerbations
Verified date | April 2024 |
Source | The Hospital for Sick Children |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This will be a 5 year randomized, double blind, placebo controlled trial of 7 days of oral prednisone in cystic fibrosis (CF) patients receiving intravenous (IV) antibiotic treatment for a pulmonary exacerbation at the Hospital for Sick Children and other study sub-sites across Canada. The intervention will be oral prednisone 2 mg/kg/day (max 60 mg) divided twice daily for 7 days as an adjunctive therapy for pulmonary exacerbations in CF patients who have not recovered their baseline forced expiratory volume in 1 second (FEV1) after 7 days of IV antibiotic treatment. The primary outcome will be the proportion of subjects who achieve >90% of their baseline FEV1 % predicted at day 14 of IV antibiotic treatment for a pulmonary exacerbation in each treatment arm.
Status | Completed |
Enrollment | 76 |
Est. completion date | October 7, 2023 |
Est. primary completion date | October 7, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Diagnosis of CF by newborn screening or at least one clinical feature of CF, AND either (a) or (b) as follows: 2. A documented sweat chloride = 60 mEq/L by quantitative pilocarpine iontophoresis 3. A genotype with two identifiable CF-causing mutations 4. Age > 6 years old. 5. Acute pulmonary exacerbation treated with IV antibiotics as previously defined 10% relative drop in FEV1 from baseline at the time of exacerbation 6. Informed consent by patient or parent/legal guardian 7. Ability to reproducibly perform pulmonary function testing 8. Ability to comply with medication use including the ability to take capsules, study visits and study procedures as judged by the site investigator Exclusion Criteria: 1. A respiratory tract culture positive for Burkholderia cenocepacia in the 12 months prior to enrollment 2. A respiratory tract culture positive for Mycobacterium abscessus in the 12 months prior to enrollment 3. Treatment with IV or oral corticosteroids within 2 weeks of enrollment or from Day 0-Day 7 of the pulmonary exacerbation 4. Active allergic bronchopulmonary aspergillosis (ABPA) at the time of enrollment as determined by treating physician 5. Asthma related exacerbation at enrollment as defined by the treating physician based on clinically compatible symptoms (eg. wheeze) 6. History of avascular necrosis or pathologic bone fracture 7. Uncontrolled hypertension with end organ damage 8. Active gastrointestinal bleeding 9. Status post lung or other organ transplantation 10. Pregnancy 11. Lactose intolerance (contained in placebo) 12. On Lumacaftor-Ivacaftor (Orkambi) at the time of exacerbation 13. Investigational drug use within 30 days prior to enrollment visit 14. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by site investigator |
Country | Name | City | State |
---|---|---|---|
Canada | The Governers of The University of Calgary - Alberta Health Services | Calgary | Alberta |
Canada | London Health Sciences Centre - Lawson Health Research Institute | London | Ontario |
Canada | Centre hospitalier universitaire Sainte-Justine | Montréal | Quebec |
Canada | The Centre hospitalier de l'Université de Montréal (CHUM) | Montréal | Quebec |
Canada | The Ottawa Hospital | Ottawa | Ontario |
Canada | CHU de Quebec-Universite Laval | Quebec City | Quebec |
Canada | Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval | Quebec City | Quebec |
Canada | University of Saskatchewan - Saskatchewan Health Authority | Saskatoon | Saskatchewan |
Canada | SickKids | Toronto | Ontario |
Canada | Unity Health Toronto - St. Michael's Hospital | Toronto | Ontario |
Canada | British Columbia Children's Hospital | Vancouver | British Columbia |
Canada | St. Paul's Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
The Hospital for Sick Children | Canadian Cystic Fibrosis Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Lung function recovery | The proportion of subjects who achieve >90% of their baseline FEV1 % predicted at day 14 of IV antibiotic treatment for a PEx in each treatment arm. | At 14 days of antibiotic therapy | |
Secondary | lung function recovery at follow up visit | The proportion of subjects who achieve >90% of their baseline FEV1 % predicted | 1 month follow up | |
Secondary | change in pulmonary function testing | change in pulmonary function testing | at day 7, 14 and 1 month follow up | |
Secondary | quality of life as measured by CFQ-R questionnaire | quality of life | at day 7, 14 and 1 month follow up | |
Secondary | quality of life as measured by CF Respiratory Symptom Diary | quality of life | at day 7, 14 and 1 month follow up | |
Secondary | length of hospitalization | length of hospitalization | Through study completion, up to 100 weeks | |
Secondary | time to subsequent pulmonary exacerbation | time to subsequent pulmonary exacerbation | 1 year follow up time | |
Secondary | number of adverse events | number of adverse events | At day day 14 of antibiotic therapy and 1 month follow up | |
Secondary | change in sputum inflammatory markers | change in sputum inflammatory markers | at day 7, 14 and 1 month follow up | |
Secondary | change in serum inflammatory markers | change in serum inflammatory markers | at day 7, 14 and 1 month follow up | |
Secondary | Duration of antibiotic treatment | Duration of antibiotic treatment | Through study completion, up to 100 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Completed |
NCT02421120 -
Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
|
Phase 4 | |
Completed |
NCT05407272 -
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
|
N/A | |
Recruiting |
NCT03569904 -
Markers of Pulmonary Dysbiosis Associated With Exacerbation in Patients Followed for Cystic Fibrosis
|
||
Terminated |
NCT01158937 -
Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients
|
N/A | |
Terminated |
NCT03939065 -
Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management
|
N/A | |
Completed |
NCT02109822 -
Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF
|
N/A | |
Recruiting |
NCT05276960 -
Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF
|
Phase 4 | |
Withdrawn |
NCT05641298 -
Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
|
Phase 2 | |
Recruiting |
NCT03273959 -
Program Of Exercises During The Hospitalization Of Children And Adolescents With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT05548283 -
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
|
Phase 4 |